{"groups":[{"description":"Patients receive 6-8 cycles of bevacizumab and combination chemotherapy comprising cyclophosphamide, doxorubicin, vincristine, and prednisone (A-CHOP) followed by 8 cycles of maintenance bevacizumab (MA), as outlined below. Bevacizumab 15 mg/kg is administered on day 1 over 90 min (first cycle), 60 min (second cycle) and 30 min for the subsequent cycles. CHOP (cyclophosphamide 750 mg/m 2 ; doxorubicin 50 mg/m 2 ; vincristine 1.4 mg/m2 \\[max. 2 mg\\]; prednisone 100 mg daily on days 1-5) is administered on day 1 of a 21-day cycle. Radiographic response is assessed after cycles 3, 6 and 8 of ACHOP and after cycle 8 of MA. Patients receive six cycles of ACHOP if they achieve a complete response (CR) after three cycles, eight cycles if they achieve a partial response (PR) after three cycles. Non-responders are removed from the study. ACHOP responders receive maintenance bevacizumab 15 mg/kg every 21 days for eight cycles.","id":"FG000","title":"Treatment (A-CHOP Followed by MA)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Never started treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Patient ineligible"},{"reasons":[{"groupId":"FG000","numSubjects":"13"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"8"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Other complicating disease"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Other"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"46"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"44"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"39"}],"type":"Eligible and Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"9"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"37"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"The first patient was accrued on September 14, 2006."}